AbbVie Inc. ABBV | NYSE
Next Earnings: Jul 23, 2025
Company Overview:
10 Year ABBV Performance Metrics:
ABBV Dividend Payments, Yield & Share Price charts
Unlock All Reports & Research Dividend Stocks like a BOSS!
ABBV Dividend Safety: Payout & Dividend to Free Cash Flow Ratios.
ABBV Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
ABBV Dividends Info:
ABBV Dividend History: Dates, Payments & Yield list
Below is a schedule of all ABBV dividend payments, ex-dates, share price on the day of the payment as well as TTM & forward yield
| Ex-Date | Payment Date | Amount | TTM Yield | Forward Yield | Price on Ex-Date |
|---|---|---|---|---|---|
| 04/15/2025 | 05/15/2025 | $1.640 | 3.61% | 3.61% | $181.68 |
| 01/15/2025 | 02/14/2025 | $1.640 | 3.67% | 3.4% | $192.87 |
| 10/15/2024 | 11/15/2024 | $1.550 | 3.23% | 3.76% | $164.99 |
| 07/15/2024 | 08/15/2024 | $1.550 | 3.65% | 3.21% | $193.40 |
| 04/12/2024 | 05/15/2024 | $1.550 | 3.73% | 3.79% | $163.79 |
| 01/12/2024 | 02/15/2024 | $1.550 | 3.69% | 3.51% | $176.59 |
| 10/12/2023 | 11/15/2023 | $1.480 | 3.99% | 4.3% | $137.60 |
| 07/13/2023 | 08/15/2023 | $1.480 | 4.38% | 3.89% | $152.12 |
| 04/13/2023 | 05/15/2023 | $1.480 | 3.55% | 4.04% | $146.59 |
| 01/12/2023 | 02/15/2023 | $1.480 | 3.75% | 3.92% | $151.06 |
| 10/13/2022 | 11/15/2022 | $1.410 | 3.95% | 3.69% | $153.04 |
| 07/14/2022 | 08/15/2022 | $1.410 | 3.68% | 3.96% | $142.29 |
| 04/13/2022 | 05/16/2022 | $1.410 | 3.41% | 3.63% | $155.47 |
| 01/13/2022 | 02/15/2022 | $1.410 | 3.98% | 3.9% | $144.76 |
| 10/14/2021 | 11/15/2021 | $1.300 | 4.77% | 4.45% | $116.84 |
| 07/14/2021 | 08/16/2021 | $1.300 | 4.33% | 4.39% | $118.41 |
| 04/14/2021 | 05/14/2021 | $1.300 | 4.68% | 4.47% | $116.43 |
| 01/14/2021 | 02/16/2021 | $1.300 | 4.34% | 4.99% | $104.20 |
| 10/14/2020 | 11/16/2020 | $1.180 | 5.48% | 4.8% | $98.36 |
| 07/14/2020 | 08/14/2020 | $1.180 | 4.66% | 4.96% | $95.07 |
| 04/14/2020 | 05/15/2020 | $1.180 | 5.48% | 5.2% | $90.71 |
| 01/14/2020 | 02/14/2020 | $1.180 | 4.98% | 5.02% | $94.05 |
| 10/11/2019 | 11/15/2019 | $1.070 | 5.81% | 4.83% | $88.63 |
| 07/12/2019 | 08/15/2019 | $1.070 | 5.93% | 6.8% | $62.98 |
| 04/12/2019 | 05/15/2019 | $1.070 | 5.03% | 5.43% | $78.78 |
| 01/14/2019 | 02/15/2019 | $1.070 | 4.66% | 5.29% | $80.85 |
| 10/12/2018 | 11/15/2018 | $0.960 | 3.96% | 4.26% | $90.14 |
| 07/12/2018 | 08/15/2018 | $0.960 | 3.42% | 3.94% | $97.45 |
| 04/12/2018 | 05/15/2018 | $0.960 | 3.2% | 3.69% | $104.18 |
| 01/11/2018 | 02/15/2018 | $0.710 | 2.65% | 2.47% | $114.90 |
| 10/12/2017 | 11/15/2017 | $0.640 | 2.8% | 2.73% | $93.76 |
| 07/12/2017 | 08/15/2017 | $0.640 | 3.46% | 3.64% | $70.34 |
| 04/11/2017 | 05/15/2017 | $0.640 | 3.77% | 3.84% | $66.67 |
| 01/11/2017 | 02/15/2017 | $0.640 | 3.84% | 4.15% | $61.65 |
| 10/12/2016 | 11/15/2016 | $0.570 | 3.72% | 3.63% | $62.87 |
| 07/13/2016 | 08/15/2016 | $0.570 | 3.43% | 3.38% | $67.39 |
| 04/13/2016 | 05/16/2016 | $0.570 | 3.66% | 3.65% | $62.45 |
| 01/13/2016 | 02/16/2016 | $0.570 | 4.1% | 4.26% | $53.51 |
| 10/13/2015 | 11/16/2015 | $0.510 | 3.75% | 3.4% | $60.01 |
| 07/13/2015 | 08/14/2015 | $0.510 | 2.77% | 2.97% | $68.65 |
| 04/13/2015 | 05/15/2015 | $0.510 | 3.01% | 3.09% | $65.99 |
| 01/13/2015 | 02/13/2015 | $0.490 | 2.76% | 3.38% | $58.05 |
| 10/10/2014 | 11/17/2014 | $0.420 | 3.02% | 2.58% | $65.04 |
| 07/11/2014 | 08/15/2014 | $0.420 | 2.98% | 3.12% | $53.90 |
| 04/11/2014 | 05/15/2014 | $0.420 | 3.49% | 3.19% | $52.69 |
| 01/13/2014 | 02/14/2014 | $0.400 | 3.21% | 3.15% | $50.73 |
| 10/10/2013 | 11/15/2013 | $0.400 | 3.5% | 3.3% | $48.44 |
| 07/11/2013 | 08/15/2013 | $0.400 | 2.74% | 3.7% | $43.21 |
| 04/11/2013 | 05/15/2013 | $0.400 | 1.85% | 3.48% | $46.03 |
| 01/11/2013 | 02/15/2013 | $0.400 | 1.18% | 4.26% | $37.58 |
Projected Future Returns & Dividends for ABBV
Based on past 10-year performance, here are ABBV growth metrics:
Share price CAGR of +10.83%
Dividend CAGR of +12.39%
Using ABBV CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| ABBV (DRIP) | ABBV - No DRIP | |
|---|---|---|
| Current Price | $189.54 | $189.54 |
| Start Shares | 52.76 | 52.76 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 76.16 | 52.76 |
| Dividends Payment | $5.27 | $5.27 |
| Annual Dividends | $1,607 | $1,113 |
| Yield on cost | 16.07% | 11.13% |
| Share Price | $478.30 | $478.30 |
| Total Dividends | $7,671 | $6,189 |
| Final Value | $36,429 | $31,424 |
NOTE: Above numbers are our estimate based on ABBV's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Company Info
AbbVie Inc. (ABBV) had its IPO on 2013-01-02, and is trader on NYSE stock exchange.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
ABBV website: https://www.abbvie.com
